# CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

> **NCT03263208** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- B-cell Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** CD19 CAR-T

## Key facts

- **NCT ID:** NCT03263208
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-16
- **Primary completion:** 2019-01
- **Final completion:** 2019-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263208, "CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03263208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*